RT Journal Article
SR Electronic
T1 Immune thrombocytopenia: No longer ‘idiopathic’
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 358
OP 373
DO 10.3949/ccjm.78gr.10005
VO 78
IS 6
A1 Keith McCrae
YR 2011
UL http://www.ccjm.org/content/78/6/358.abstract
AB Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.